We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Emergent (EBS) Gets Extra $23M for COVID-19 Vaccine Production
Read MoreHide Full Article
Emergent BioSolutions Inc. (EBS - Free Report) announced that the U.S. Department of Health & Human Services’ Biomedical Advanced Research and Development Authority, or BARDA, has increased its task order by $23 million to support further expansion of manufacturing capacity for Johnson & Johnson’s (JNJ - Free Report) COVID-19 vaccine.
Shares of Emergent have declined 10.2% so far this year against the industry’s increase of 0.4%.
We remind investors that last week J&J and Emergent issued statements that a batch of drug substance for manufacturing the former’s COVID-19 vaccine at Emergent’s Bayview facility had failed to meet quality standards. A few weeks ago, reportedly, workers at Emergent's Bayview facility had mixed up ingredients of J&J’s and AstraZeneca’s (AZN - Free Report) vaccines.
Emergent has partnered with both J&J and AstraZeneca to help manufacture their respective COVID-19 vaccines. The incident reportedly ruined 15 million doses of J&J’s vaccine. U.S. health officials have now put J&J in charge of the facility, implying that the plant will now only make J&J’s vaccine to rule out any future mix ups. The facility will cease production of AstraZeneca shots.
Despite the potential delay in shipments due to the Bayview blunder, J&J targets to deliver 24 million doses to the U.S. government in April and 100 million doses by the end of May.
Please note that AstraZeneca’s vaccine has not yet been granted EUA in the United States by the FDA.
In a separate press release, Emergent announced top-line data from the NIAID-sponsored phase III ITAC study (INSIGHT-013) evaluating four immunoglobulin candidates, including Emergent’s investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG), for the treatment of hospitalized patients with COVID-19.
The above-mentioned study investigated the safety and efficacy of four immunoglobulin candidates plus standard of care as compared to placebo plus standard of care in the given patient population.
Data from the study showed that the addition of anti-SARS-CoV-2 hyperimmunoglobulin to standard of care, inclusive of Gilead’s (GILD - Free Report) Veklury (remdesivir), for hospitalized adult COVID-19 patients with symptoms for less than 12 days did not provide clinical benefit when compared to standard of care plus placebo.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
Image: Bigstock
Emergent (EBS) Gets Extra $23M for COVID-19 Vaccine Production
Emergent BioSolutions Inc. (EBS - Free Report) announced that the U.S. Department of Health & Human Services’ Biomedical Advanced Research and Development Authority, or BARDA, has increased its task order by $23 million to support further expansion of manufacturing capacity for Johnson & Johnson’s (JNJ - Free Report) COVID-19 vaccine.
Shares of Emergent have declined 10.2% so far this year against the industry’s increase of 0.4%.
We remind investors that last week J&J and Emergent issued statements that a batch of drug substance for manufacturing the former’s COVID-19 vaccine at Emergent’s Bayview facility had failed to meet quality standards. A few weeks ago, reportedly, workers at Emergent's Bayview facility had mixed up ingredients of J&J’s and AstraZeneca’s (AZN - Free Report) vaccines.
Emergent has partnered with both J&J and AstraZeneca to help manufacture their respective COVID-19 vaccines. The incident reportedly ruined 15 million doses of J&J’s vaccine. U.S. health officials have now put J&J in charge of the facility, implying that the plant will now only make J&J’s vaccine to rule out any future mix ups. The facility will cease production of AstraZeneca shots.
Despite the potential delay in shipments due to the Bayview blunder, J&J targets to deliver 24 million doses to the U.S. government in April and 100 million doses by the end of May.
Please note that AstraZeneca’s vaccine has not yet been granted EUA in the United States by the FDA.
In a separate press release, Emergent announced top-line data from the NIAID-sponsored phase III ITAC study (INSIGHT-013) evaluating four immunoglobulin candidates, including Emergent’s investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG), for the treatment of hospitalized patients with COVID-19.
The above-mentioned study investigated the safety and efficacy of four immunoglobulin candidates plus standard of care as compared to placebo plus standard of care in the given patient population.
Data from the study showed that the addition of anti-SARS-CoV-2 hyperimmunoglobulin to standard of care, inclusive of Gilead’s (GILD - Free Report) Veklury (remdesivir), for hospitalized adult COVID-19 patients with symptoms for less than 12 days did not provide clinical benefit when compared to standard of care plus placebo.
Zacks Rank
Emergent currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 3 crypto-related stocks now >>